Genmab axes an ADC development program after the data fail to impress
Genmab $GMAB has opted to ax one of its antibody-drug conjugates after watching it flop in the clinic.
The Danish biotech reported Tuesday that it decided to kill their program for enapotamab vedotin after the data gathered from expansion cohorts failed to measure up. According to the company:
While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers. Accordingly, the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.
This was one of a string of 5 drug programs the biotech talked up as it executed a large IPO on Nasdaq last year. Genmab is looking to develop its own pipeline as it looks to build on the success of Darzalex, partnered with J&J. And now the company plans to switch focus to other experimental drugs in the pipeline.
The ADC uses linker tech in-licensed from Seagen, one of the leaders in the field.
Researchers used an antibody conjugated to the antimitotic drug monomethyl auristatin E. AXL is a signaling molecule overexpressed in several hematologic and solid malignancies and investigators worked on the theory that overexpression drives “epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.”